Lisata Therapeutics, Inc. to acquire Marea Therapeutics, Inc.

Lisata Therapeutics, Inc has agreed to acquire Marea Therapeutics, Inc in a strategic acquisition within the healthcare sector. The transaction involves consideration paid through shares, reflecting an equity-based structure for the deal. Both entities are based in the United States, indicating a domestic consolidation of assets and capabilities within the American healthcare market. This arrangement allows Lisata to integrate Marea’s operations and intellectual property into its existing portfolio without disclosing specific financial terms or valuation metrics at this stage. The focus remains on the structural elements of the merger rather than the monetary value exchanged between the parties involved in this corporate restructuring effort.

The deal was announced on 17 September 2026, marking a significant step in the strategic alignment of these two healthcare organisations. Although the precise financial details remain undisclosed, the share-based consideration suggests a mutual agreement on future value creation through combined operational synergies. This approach is common in sectors where intellectual property and research capabilities are paramount assets for long-term growth and competitive advantage in the marketplace. The transaction has reached its final stage of completion, confirming that all necessary internal approvals and procedural requirements have been satisfied by both Lisata Therapeutics and Marea Therapeutics to finalise the acquisition process effectively.